Merck & Co., Inc. (MRK)’s Late-Stage Breakdown

Page 1 of 2

Merck & Co., Inc. (NYSE:MRK)The Food and Drug Administration cancelled an advisory meeting planned for Merck & Co., Inc. (NYSE:MRK)’s post-surgery drug sugammadex. It’s another blow to Merck & Co., Inc. (NYSE:MRK) as investors pay close attention to the beleaguered R&D department now turned over to Roger Perlmutter.

Merck highlighted its top five late-stage projects during the full-year 2011 conference call last February: sugammadex, insomnia treatment suvorexant, HPV vaccine V503, osteoporosis drug odanacatib, and cholesterol drug Tredaptive. All of these drugs have since encountered major problems, and investors are nervous.

Merck & Co., Inc. (NYSE:MRK) has spent $8 billion a year for research and development, but currently has little to show for it. Can the newly returned Perlmutter rescue Merck’s R&D?

Sugammadex hits a bump

Sugammadex is meant to reverse the after-effects of muscle relaxants administered during surgery. If approved, sugammadex would become a first-in-class selective relaxant binding agent, or SRBA. But the drug has had Food and Drug Administration issues since its first new drug application was filed in 2008.

While an early advisory panel had recommended the drug, the FDA issued a “not-approvable” action letter due to allergic reaction concerns. The resubmitted NDA was accepted earlier this year before the panel was cancelled this week. A panel cancellation doesn’t immediately equal the failure of the drug.

But the cancellation serves as one last potential setback for the top five drugs that Merck & Co., Inc. (NYSE:MRK) touted as its late-stage future. Let’s look at what happened to the other four.

Faltering four

The highly anticipated insomnia drug suvorexant recently received a complete response letter centered around dosing. The FDA found that Merck & Co., Inc. (NYSE:MRK)’s suggested 30 to 40 mg dosage was not supported by enough safety data to warrant approval. A low dose of 10 mg was recommended for most patients, but 5 mg was recommended for those taking certain medications that could cause a drug interaction.

Merck said that additional safety or efficacy trials aren’t needed for the 10 mg dose but will require a manufacturing study. The FDA could require additional trials for the 5 mg dosage. Merck’s currently in talks with the FDA to determine the next step for suvorexant.

HPV vaccine V503 hasn’t hit a regulatory roadblock, but it could prove unnecessary. V503 is meant to back up Merck’s market-dominating Gardasil vaccine while offering protection from an additional six genotypes of the disease. But there’s reason to believe that those extra genotypes don’t need to be covered, which would make V503 redundant at best.

Merck & Co., Inc. (NYSE:MRK) announced in the fourth quarter 2012 report that osteoporosis drug odanacatib required some additional safety and efficacy trial from an extension study. That meant pushing back the regulatory filing from the first half of this year to some time in 2014. Merck remained mum on exactly why it was necessary to gather more information.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!